Scientists probe immune System's response to new First-Line cancer pill
NCT ID NCT07428707
Summary
This study aims to understand how the drug pirtobrutinib affects the immune system when used as a first treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers will enroll about 30 adults with untreated CLL or SLL to take the drug daily and closely monitor changes in their immune cells and cancer. The main goal is to gather detailed biological information, not primarily to test how well the drug works as a treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL LYMPHOCYTIC LYMPHOMA (SLL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.